Cardiovascular
Ozempic compensating for Wegovy’s supply shortage due to high demand
In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in…
Royalty Pharma acquires royalty interest in olpasiran for $250m
Royalty Pharma has purchased a royalty interest in Amgen’s small interfering ribonucleic acid (siRNA) therapy, olpasiran, from Arrowhead Pharmaceuticals for…
GSK speeds up the race to bring first RSV vaccine for older adults to market
After decades of setbacks, the respiratory syncytial virus (RSV) vaccine field has bounced back with positive Phase III trial results…
Myovant Sciences rejects $2.5bn takeover bid from Sumitomo Pharma
Myovant Sciences has rejected an acquisition offer from Sumitovant Biopharma and its wholly owned subsidiary, Sumitomo Pharma. The news of the offer…
US FDA grants Fast Track status for Lilly’s tirzepatide to treat obesity
The US Food and Drug Administration (FDA) has granted Fast Track designation for Eli Lilly and Company’s tirzepatide to treat adults with…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Rivus raises $132m to advance clinical development of obesity treatment
Rivus Pharmaceuticals has raised $132m in a Series B funding round to clinically advance its lead candidate, HU6, for the…
Amarin makes moves towards global expansion of Vazkepa
Amarin is going full steam ahead with its plans for global expansion of its cardiovascular drug Vazkepa (Vascepa/icosapent ethyl). Last…
Rocket agrees to acquire biotech firm Renovacor
Rocket Pharmaceuticals has entered a definitive agreement for the acquisition of biotechnology firm Renovacor in an all-stock equity deal worth nearly $53m, or…
How environmental factors could influence disease and drugs
The study of lifetime exposures, also known as the “exposome”, is providing a new perspective on how environmental and social…
Rare Disease Spotlight- Oncology therapies dominate the orphan drug landscape
Rare diseases affect only a small percentage of the population, and since their pathophysiology has historically been poorly studied, there…
Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure
US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with…
US FDA grants Fast Track status for Anthos Therapeutics’ abelacimab
The US Food and Drug Administration (FDA) has granted Fast Track designation for Anthos Therapeutics’ fully human monoclonal antibody abelacimab…
Diabetic macular oedema market expected to grow to $11.1bn globally by 2031
The diabetic macular oedema (DME) market is anticipated to reach values of $11.1bn in 2031 across the seven major markets…
Bayer agrees to pay $40m to resolve claims on three drugs
Bayer has agreed to make a payment of $40m for settling claims over the alleged violations of the False Claims…
FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivity
The diabetic macular oedema (DME) space recently witnessed a new approval; the US Food and Drug Administration (FDA) announced the…